Suppr超能文献

H-2组胺拮抗剂甲硫米特对十二指肠溃疡患者基础和刺激状态下胃H⁺及胃蛋白酶分泌的抑制作用

Inhibition of basal and stimulated gastric H+ and pepsin secretion in duodenal ulcer patients by metiamide, an H-2 histamine antagonist.

作者信息

Bajaj S C, Hirschowitz B I

出版信息

Am J Dig Dis. 1976 Jul;21(7):557-62. doi: 10.1007/BF01464763.

Abstract

Metiamide was given orally in one dose of 200 mg in 23 sutdies in patients with duodenal ulcer, 4 in the basal state, 11 during histamine infusion, and 8 before insulin hypoglycemia stimulation. In the latter 8 patients insulin was given at another time without metiamide. In 17 studies acid secretion was suppressed by metiamide--up to 75% in the basal state, 53% after histamine, and 80% after insulin. Pepsin secretion was reduced to the same extent as H+ in the histamine studies but not in the basal (57%) or insulin (44%) studies, so that in the latter pepsin/acid ratios were 3-fold greater than in controls. Blood levels of metiamide were measured in 17 studies. In 10 out of 11 who showed inhibition of 40% or more, peak blood levels of metiamide were 0.45 mug/ml to 1.25 mug/ml. In 5 of 6 who did not show inhibition, blood levels were 0.05-0.4 mug/ml; in the sixth it was 0.8 mug/ml. Therefore a critical blood level for suppression of basal or stimulated secretion appears to be approximately 0.45 mug/ml.

摘要

在23项十二指肠溃疡患者的研究中,甲硫米特口服单剂量为200毫克,其中4例处于基础状态,11例在组胺输注期间,8例在胰岛素低血糖刺激前。在这8例患者中,胰岛素在另一时间给予,未使用甲硫米特。在17项研究中,甲硫米特抑制了胃酸分泌——基础状态下高达75%,组胺刺激后为53%,胰岛素刺激后为80%。在组胺研究中,胃蛋白酶分泌减少的程度与H+相同,但在基础状态(57%)或胰岛素(44%)研究中并非如此,因此在后者中胃蛋白酶/酸的比值比对照组高3倍。在17项研究中测量了甲硫米特的血药浓度。在11例中有10例显示抑制率达到40%或更高,甲硫米特的血药峰浓度为0.45微克/毫升至1.25微克/毫升。在6例未显示抑制作用的患者中有5例,血药浓度为0.05 - 0.4微克/毫升;第6例为0.8微克/毫升。因此,抑制基础或刺激分泌的临界血药浓度似乎约为0.45微克/毫升。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验